|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2024―Feb―14 |
Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection |
Inès Boussen, Maud Salmona, Flore Sicre De Fontbrune, Aliénor Xhaard, Nathalie De Castro, Constance Delaugerre, et al. (+2) Marie-Laure Chaix, Jean-Michel Molina |
2 |
[GO] |
2023―Oct―20 |
Subacute thyroiditis following COVID-19 vaccination: Case presentation |
Aleksandra Z Tomic, Sonja S Zafirovic, Zoran M Gluvic, Vladimir S Samardzic, Mirjana T Macvanin, Maja LJ Radunovic, Esma R Isenovic |
3 |
[GO] |
2023―Sep―06 |
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach |
Eslam B Elkaeed, Bshra A Alsfouk, Tuqa H Ibrahim, Reem K Arafa, Hazem Elkady, Ibrahim M Ibrahim, et al. (+2) Ibrahim H Eissa, Ahmed M Metwaly |
4 |
[GO] |
2023―Jun―29 |
Letter to the editor on use of antibodies from convalescent sera in the treatment of moderate and severe Covid-19 infection |
Sarah B Nahhal, Bassem Awada, Joe-David Azzo, Rayyan Wazzi-Mkahal, Souha Kanj, Zeina A Kanafani |
5 |
[GO] |
2022―Dec―21 |
A favipiravir-induced angioedema and urticaria in a COVID-19 patient |
Figen Ergur Ozturk, Ayperi Ozturk, Hale Ates |
6 |
[GO] |
2022―Apr―14 |
Synthetic Peptides outside the Spike Protein Heptad Repeat Regions as Potent Inhibitors of Sars-Associated Coronavirus |
Bo-Jian Zheng, Yi Guan, Ming-Liang He, Hongzhe Sun, Lanying Du, Ying Zheng, et al. (+13) Kin-Ling Wong, Honglin Chen, Ying Chen, Linyu Lu, Julian A Tanner, Rory M Watt, Neri Niccolai, Andrea Bernini, Ottavia Spiga, Patrick CY Woo, Hsiang-fu Kung, Kwok-Yung Yuen, Jian-Dong Huang |
7 |
[GO] |
2022―Apr―14 |
Indomethacin Has a Potent Antiviral Activity against Sars Coronavirus |
Carla Amici, Antonino Di Caro, Alessandra Ciucci, Lucia Chiappa, Concetta Castilletti, Vito Martella, et al. (+4) Nicola Decaro, Canio Buonavoglia, Maria R Capobianchi, M Gabriella Santoro |
8 |
[GO] |
2022―Apr―14 |
Severe Acute Respiratory Syndrome Coronavirus Entry as a Target of Antiviral Therapies |
Jens H Kuhn, Wenhui Li, Sheli R Radoshitzky, Hyeryun Choe, Michael Farzan |
9 |
[GO] |
2022―Apr―14 |
Protection of Mammalian Cells from Severe Acute Respiratory Syndrome Coronavirus Infection by Equine Neutralizing Antibody |
Xiliang Wang, Bing Ni, Xinan Du, Guangyu Zhao, Wenda Gao, Xinfu Shi, et al. (+12) Songle Zhang, Liangyan Zhang, Dong Wang, Deyan Luo, Li Xing, Haiyan Jiang, Wanling Li, Man Jiang, Liwei Mao, Yangdong He, Yu Xiao, Yuzhang Wu |
10 |
[GO] |
2022―Apr―14 |
Probing the Structure of the Sars Coronavirus Using Scanning Electron Microscopy |
Yun Lin, Xiyun Yan, Wuchun Cao, Chaoying Wang, Jing Feng, Jinzhu Duan, Sishen Xie |
11 |
[GO] |
2022―Apr―14 |
Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine |
Jiang-Tao Lin, Jian-San Zhang, Nan Su, Jian-Guo Xu, Nan Wang, Jiang-Ting Chen, et al. (+21) Xin Chen, Yu-Xuan Liu, Hong Gao, Yu-Ping Jia, Yan Liu, Rui-Hua Sun, Xu Wang, Dong-Zheng Yu, Rong Hai, Qiang Gao, Ye Ning, Hong-Xia Wang, Ma-Chao Li, Biao Kan, Guan-Mu Dong, Qi An, Ying-Qun Wang, Jun Han, Chuan Qin, Wei-Dong Yin, Xiao-Ping Dong |
12 |
[GO] |
2022―Apr―14 |
Inhibition of Replication and Infection of Severe Acute Respiratory Syndrome-Associated Coronavirus with Plasmid-Mediated Interference RNA |
Bing Ni, Xinfu Shi, Yang Li, Wenda Gao, Xiliang Wang, Yuzhang Wu |
13 |
[GO] |
2022―Apr―14 |
Human Coronaviruses: What Do They Cause? |
Lia Van Der Hoek |
14 |
[GO] |
2022―Apr―14 |
Neuraminidase Inhibitors and their Role in Avian and Pandemic Influenza |
Martin Crusat, Menno D De Jong |
15 |
[GO] |
2022―Apr―14 |
Discovery and Characterization of the 1918 Pandemic Influenza Virus in Historical Context |
Jeffery K Taubenberger, Johan V Hultin, David M Morens |
16 |
[GO] |
2022―Mar―07 |
Antiviral prophylaxis for hepatitis B virus in COVID-19 patients treated with immunosuppressive drug therapy |
Antonio Mastroianni, Sonia Greco, Luciana Chidichimo, Maria Vittoria Mauro, Filippo Urso, Valeria Vangeli |
17 |
[GO] |
2022―Mar―02 |
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19 |
Tomas Cihlar, Richard L. Mackman |
18 |
[GO] |
2022―Feb―26 |
Herpes simplex virus reactivation in patients with COVID-19 and acute respiratory distress syndrome: a prospective cohort study |
Alessandro F Chiesa, Micol Pallanza, Gladys Martinetti, Fabio Lanzi, Marco Previsdomini, Alberto Pagnamenta, Luigia Elzi |
19 |
[GO] |
2021―Oct―19 |
Real-life findings on the impact of the COVID-19 pandemic on HIV care |
Arturo Ciccullo, Gianmaria Baldin, Alberto Borghetti, Simona Di Giambenedetto |
20 |
[GO] |
2021―Sep―02 |
Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study |
Jeong Eun Lee, Soon Ok Lee, Jeonghun Heo, Dong Wan Kim, Mi Ran Park, Hyunjin Son, et al. (+4) Dongkeun Kim, Kye-Hyung Kim, Shinwon Lee, Sun Hee Lee |
21 |
[GO] |
2021―Mar―11 |
The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review |
Jienchi Dorward, Oghenekome Gbinigie, Ting Cai, Nia W Roberts, Nigel Garrett, Gail Hayward, Christopher C Butler |
22 |
[GO] |
2021―Feb―22 |
COVID-19 and hepatitis B infection |
Saleh A Alqahtani, Maria Buti |
23 |
[GO] |
2021―Jan―18 |
Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity |
Mattia Trunfio, Elena Salvador, Alberto Gaviraghi, Sabrina Audagnotto, Letizia Marinaro, Ilaria Motta, et al. (+6) Riccardo Casciaro, Valeria Ghisetti, Carmen Fava, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno |
24 |
[GO] |
2020―Aug―03 |
Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system |
Michael A Jarvis, Frederick A Hansen, Kyle Rosenke, Elaine Haddock, Christopher Rollinson, Simon Rule, et al. (+3) Graham Sewell, Andrew Hughes, Heinz Feldmann |
25 |
[GO] |
2020―Jun―26 |
SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection |
Elise J Smolders, Lindsey HM te Brake, David M Burger |
26 |
[GO] |
2020―Jun―04 |
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19 |
Xiangyang Xie, Yuanliang Jiang, Yuan Zeng, Hui Liu |